Cleaning Validation: Complete Guide for Health - Based Approach in Chemical Cross - Contamination Risk Assessment

References

1. 1.↵
   1. Walsh A.

   Cleaning Validation for the 21st Century: Overview of New ISPE Cleaning Guide. Pharmaceutical Engineering, 2011, 31 (6), 1–7.

   OpenUrl
2. 2.↵
   1. Sussman R. G.,
   2. Schatz A. R.,
   3. Kimmel T. A.,
   4. Ader A.,
   5. Naumann B. D.,
   6. Weideman P. A.

   Identifying and Assessing Highly Hazardous Drugs within Quality Risk Management Programs. Regul. Toxicol. Pharmacol. 2016, 79, S11–S18.

   OpenUrl
3. 3.↵
   1. Crevoisier M.,
   2. Barle E. L.,
   3. Flueckiger A.,
   4. Dolan D. G.,
   5. Ader A.,
   6. Walsh A.

   Cleaning Limits - Why the 10-ppm Criterion Should be Abandoned. Pharmaceutical Technology, 2016, 40 (1), 52–56.

   OpenUrl
4. 4.↵
   1. Bruttmann G.,
   2. Pedrali P.

   Loratadine (SCH29851) 40 mg Once Daily Versus Terfenadine 60 mg Twice Daily in the Treatment of Seasonal Allergic Rhinitis. J. Int. Med. Res. 1987, 15 (2), 63–70.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Brennan B. J.,
   2. Wang K.,
   3. Blotner S.,
   4. Magnusson M. O.,
   5. Wilkins J. J.,
   6. Martin P.,
   7. Solsky J.,
   8. Nieforth K.,
   9. Wat C,
   10. Grippo J. F.

   Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment. Antimicrob. Agents Chemother. 2013, 57 (12), 6097–6105.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   European Medicines Agency. Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. EMA: (2014) https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-setting-health-based-exposure-limits-use-risk-identification-manufacture-different_en.pdf (accessed Feb 10, 2018).
7. 7.↵
   Europe, the Middle East and Africa, (2003). ICH guideline Q3C (R6) on Impurities: Guideline for Residual Solvents. International Conference of Harmonisation, 68 (December 2016), 35. Retrieved from https://www.ema.europa.eu/en/documents/scientific-guideline/q3c-r6-impurities-guideline-residual-solvents-step-2b_en.pdf (Accessed February 10, 2018).

   OpenUrl
8. 8.↵
   1. Wharf C.,
   2. Kingdom U.

   V Eterinary M Edicinal P Roducts. Exposure, 2010, 44 (May), 1–20.

   OpenUrl
9. 9.↵
   ICH-3D-quality. 0013-Guideline for Elemental Impurities Q3D. Ich, 2014, (December), 1–75.
10. 10.↵
    1. Dorne J. L. C. M.,
    2. Renwick A. G.

    The Refinement of Uncertainty/Safety Factors in Risk Assessment by the Incorporation of Data on Toxicokinetic Variability in Humans. Toxicol. Sci. 2005, 86 (1), 20–26.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Reichard J. F.,
    2. Maier M. A.,
    3. Naumann B. D.,
    4. Pecquet A. M.,
    5. Pfister T.,
    6. Sandhu R.,
    7. Sargent E. V.,
    8. Streeter A. J.,
    9. Weideman P. A.

    Toxicokinetic and Toxicodynamic Considerations when Deriving Health-Based Exposure Limits for Pharmaceuticals. Regul. Toxicol. and Pharmacol. https://doi.org/10.1016/j.yrtph.2016.05.027 2016, 79, S67–S78.

    OpenUrl
12. 12.↵
    1. Devaux P.

    , Cleaning Validation: Defining Limits and Doing MACO Calculations. https://ispenordic.nemtilmeld.dk/images/descriptions/13540/20_april/02_Defining_Limits_and_Doing_MACO_Calculations__by_Pierre_Devaux.pdf (accessed February 10, 2018).
13. 13.↵
    1. Bonneure A.,
    2. Buggy T.

    Guidance on Aspects of Cleaning Validation in Active Pharmaceutical Ingredient Plants. https://apic.cefic.org/pub/APICCleaningValidationGuide-updateSeptember2016-final.pdf (Accessed February 10, 2018).
14. 14.↵
    U.S. Food and Drug Administration, Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry. 2016. https://www.fda.gov/downloads/Drugs/Guidances/ucm073497.pdf.